Peptides vs. Anabolic Steroids: Mechanisms, Evidence and Risk

Two different kinds of drug

Lifters compare peptides and anabolic-androgenic steroids (AAS) all the time, usually as a contest over which one is better. A more useful question is what each one does and how much human evidence sits behind it.

AAS act directly on the androgen receptor in muscle and almost every other tissue, and their effect on muscle size and strength has been measured in controlled human trials. The peptides most often compared with them work on other pathways, either through the body's own growth hormone or through repair signals studied mostly in animals.

A popular forum framing says steroids are a blunt instrument and peptides a precise one with few side effects. Part of that holds up: these peptides don't act on the androgen receptor, so they don't cause androgenic side effects. But a short side-effect list for a peptide often reflects a short list of studies, not a proven safety record.

How they work

AAS and the androgen receptor

Testosterone and its synthetic relatives bind the androgen receptor, and in muscle cells that raises protein synthesis. The same receptor sits in skin, hair follicles, the prostate, the heart and the brain. A dose taken for muscle reaches all of them, which explains much of the AAS side-effect list.

Outside testosterone also tells the brain to cut its own signal to the testes. An Endocrine Society scientific statement lists suppression of this hormone axis, and hypogonadism after stopping, among the main endocrine effects of AAS use in men. That is the "shutdown" steroid users plan post-cycle recovery around.

Peptides work on separate pathways

The peptides in this comparison don't bind the androgen receptor. They fall into a few groups:

• Growth hormone secretagogues such as ipamorelin and GHRP-2 act on the ghrelin receptor (GHSR) in the pituitary and trigger a pulse of the body's own growth hormone. GHRH analogues such as CJC-1295 act on a different pituitary receptor. This is still a whole-body hormonal effect, because growth hormone and IGF-1 rise everywhere, not only in muscle. Our article on how CJC-1295 and ipamorelin work together covers the pituitary side.
• Repair peptides such as BPC-157 and TB-500. In rodent and cell studies, BPC-157 is linked to growth-factor signaling, new blood vessel formation and lower inflammatory cytokines. "TB-500" usually means a short synthetic fragment of thymosin beta-4 (Ac-LKKTETQ) that anti-doping chemists characterized in 2012, not the full 43-amino-acid protein. Human trials of full thymosin beta-4 tell us little about the fragment.
• Melanocortin peptides such as melanotan II act on melanocortin receptors, which affect pigmentation and sexual function. They aren't anabolic; they appear in these comparisons because the same people use them.

What the human evidence shows

Muscle and strength

The best-known controlled trial of high-dose testosterone, published in 1996, randomized 43 healthy men to 600 mg of testosterone enanthate or placebo by weekly injection for 10 weeks, with or without supervised weight training. Men given testosterone plus training gained about 6.1 kg of fat-free mass and added about 22 kg to their bench press and 38 kg to their squat. Testosterone raised muscle size and strength even in men who didn't train. The authors called the dose supraphysiologic, and it was given under medical monitoring.

No peptide has shown anything similar in a trial. The closest human data come from the growth hormone secretagogue class. In a 2-year randomized trial of 65 healthy adults aged 60-81, MK-677 (ibutamoren, an oral small molecule that acts on the same ghrelin receptor, so not itself a peptide) at 25 mg a day raised fat-free mass by about 1.1 kg, while the placebo group lost about 0.5 kg. Strength and function didn't change. The populations differ, so this isn't a head-to-head comparison, but the size of the gap is clear. For ipamorelin, GHRP-2 and CJC-1295, the published human data cover growth hormone release and tolerability, not muscle outcomes.

Users commonly describe stacking CJC-1295 without DAC (Mod GRF 1-29) at 100-300 mcg with ipamorelin, often at bedtime, and report better sleep and a leaner look. Those reports are uncontrolled, and we found no controlled trial of that combination.

Injury repair

This is where peptides are said to win. The animal data are consistent: a 2025 systematic review of BPC-157 in orthopaedic sports medicine found 36 studies, 35 of them preclinical, reporting better recovery in rodent muscle, tendon, ligament and bone injury models. The one clinical study was a series in which 7 of 12 people with chronic knee pain reported relief for more than six months after a single knee injection. The review found no clinical safety data.

A 2025 pilot then gave intravenous BPC-157 (10 mg, then 20 mg the next day) to 2 adults and saw no side effects or changes in standard blood markers. As of October 2026, no controlled human trial of BPC-157 has published results; a placebo-controlled pilot in about 30 patients after rotator cuff surgery is registered to start in January 2027. For the TB-500 fragment, we found no published human study at all. Our BPC-157 and TB-500 comparison covers the animal data.

Users commonly report 250-500 mcg of BPC-157 a day by subcutaneous injection, often near the injury, and TB-500 at a few milligrams once or twice a week. Accounts range from clear improvement within weeks to no noticeable change. Natural healing, placebo effects and uneven product quality all make these reports hard to read.

On the steroid side, the Endocrine Society statement lists tendon rupture among the musculoskeletal effects of AAS. The authors attribute it partly to muscles outgrowing their tendons and partly to possible direct effects on tendon structure. Whether any peptide offsets that risk in people is unknown.

Fat loss

Community guides often credit growth hormone secretagogues with strong fat loss. The MK-677 trial found no significant change in total or abdominal visceral fat, and limb fat rose slightly more than with placebo. Appetite went up, and mild leg swelling was common early on. For the injectable secretagogues, fat-loss claims rest on user reports.

Side effects compared

The AAS column rests on decades of case reports, cohort studies and some trials. The peptide column is shorter largely because fewer people have studied it.

The Endocrine Society authors also note that most AAS users are recreational lifters rather than competitive athletes, and that many combine several drugs at doses trials can't ethically replicate. Trial data likely understate real-world risk for that reason. The risks of peptide use have their own article.

Legal status and product quality

AAS have been Schedule III controlled substances in the US since 1991, and the 2004 Anabolic Steroid Control Act widened the legal definition. Selling them, or having them without a prescription, is a federal offense.

Most performance peptides aren't controlled substances, but they aren't approved drugs either, and the "research use only" label doesn't protect sellers. In an August 24, 2026 warning letter, FDA told one seller that despite "research use only" and "not for human consumption" labels, its website showed the products were intended as drugs for human use; it also cited the seller's bacteriostatic water sales. On July 30, 2026, the owner of Paradigm Peptides was sentenced to 70 months in prison after pleading guilty to selling unapproved drugs. He admitted the research-only claim was false, and the court found products had been adulterated with steroids.

That case shows where the two markets overlap: a vial sold as a peptide may not contain what the label says. Users often rely on third-party HPLC results, but a vendor's own certificate isn't independent verification.

As of October 2026, there's no lawful pharmacy route for BPC-157 or TB-500 either. FDA's compounding advisers reviewed both in July 2026, but FDA hasn't proposed adding any peptide to the 503A bulks list. Our guide to peptide legal status has the details.

For tested athletes, peptides offer no advantage. WADA's 2026 Prohibited List bans AAS under S1.1, names BPC-157 under S0 and TB-500 under S2.3, and lists CJC-1295, ipamorelin and GHRP-2 under S2.2.4, all prohibited at all times. For how both classes compare with SARMs, see our steroids and SARMs comparison.

Using both

Many lifters run a recovery peptide during or after a steroid cycle. No study has tested whether that protects tendons or speeds recovery from suppression. Testosterone replacement therapy is a prescription medicine for diagnosed low testosterone, monitored by a doctor; it isn't the same as a self-run cycle, and neither is a peptide vial bought online.

What we still don't know

• Whether BPC-157 helps tendon healing in people. The rotator cuff pilot planned for 2027 would be the first randomized test.
• How safe long-term growth hormone secretagogue use is in healthy young adults, since the longest trial enrolled people over 60.
• What gray-market vials actually contain, batch to batch, for both peptides and steroids.